Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis

被引:116
作者
Kim, Mi Na [1 ]
Kim, Seung Up [1 ,2 ]
Kim, Beom Kyung [1 ,2 ]
Park, Jun Yong [1 ,2 ]
Kim, Do Young [1 ,2 ]
Ahn, Sang Hoon [1 ,2 ,5 ]
Song, Ki Jun [3 ]
Park, Young Nyun [4 ]
Han, Kwang-Hyub [1 ,2 ,5 ]
机构
[1] Yonsei Univ, Dept Internal Med, Coll Med, Seoul 120752, South Korea
[2] Yonsei Univ, Inst Gastroenterol, Coll Med, Seoul 120752, South Korea
[3] Yonsei Univ, Dept Biostat, Coll Med, Seoul 120752, South Korea
[4] Yonsei Univ, Dept Pathol, Coll Med, Seoul 120752, South Korea
[5] Brain Korea 21 Project Med Sci, Seoul, South Korea
关键词
STIFFNESS MEASUREMENT; VIRUS; MANAGEMENT; THERAPY; SCORE;
D O I
10.1002/hep.27735
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Early detection of liver cirrhosis in its subclinical stage is of paramount importance to identify high-risk individuals for developing hepatocellular carcinoma (HCC). This study investigated whether transient elastography (TE) can identify patients with subclinical cirrhosis (SCC) who are at increased risk of developing HCC among chronic hepatitis B (CHB) patients without clinical evidence of cirrhosis. A total of 2,876 CHB patients without clinical cirrhosis who received TE examinations between April 2006 and December 2012 were enrolled in this prospective study. SCC was defined as a nonclinical cirrhosis, but with a liver stiffness (LS) value 13 kilopascals (kPa). Mean age of the study population was 46.1 years, and male gender was predominant (n=1,775; 61.7%). Mean LS value was 7.9 kPa, and SCC was identified in 285 (9.9%) patients. During the median follow-up period of 48.9 months (range, 6.6-96.2), HCC developed in 16 patients (13.3 per 1,000 person-years) in the SCC group and 36 (3.4 per 1,000 person-years) in the non-SCC group. Cumulative incidence rate of HCC in the SCC group was significantly higher than that in the non-SCC group (P<0.001, log-rank test). On multivariate analysis, SCC was independently associated with a risk of developing HCC, regardless of antiviral therapy (without antiviral therapy: hazard ratio [HR]: 4.680; 95% confidence interval [CI]: 1.187-18.441; P=0.027; with antiviral therapy: HR, 3.344; 95% CI: 1.526-7.328; P=0.003). Conclusion: TE can identify CHB patients with SCC who are at increased risk of developing HCC, even when cirrhosis is not clinically apparent. (Hepatology 2015;61:1851-1859)
引用
收藏
页码:1851 / 1859
页数:9
相关论文
共 38 条
[21]   Epidemiology of Hepatocellular Carcinoma [J].
Lafaro, Kelly J. ;
Demirjian, Aram N. ;
Pawlik, Timothy M. .
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 24 (01) :1-+
[22]   Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy [J].
Lee, Hye Won ;
Yoo, Eun Jin ;
Kim, Beom Kyung ;
Kim, Seung Up ;
Park, Jun Yong ;
Kim, Do Young ;
Ahn, Sang Hoon ;
Han, Kwang-Hyub .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (08) :1241-1249
[23]   Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update [J].
Liaw, Yun-Fan ;
Leung, Nancy ;
Kao, Jia-Horng ;
Piratvisuth, Teerha ;
Gane, Edward ;
Han, Kwang-Hyub ;
Guan, Richard ;
Lau, George K. K. ;
Locarnini, Stephen .
HEPATOLOGY INTERNATIONAL, 2008, 2 (03) :263-283
[24]   Hepatitis B virus infection [J].
Liaw, Yun-Fan ;
Chu, Chia-Ming .
LANCET, 2009, 373 (9663) :582-592
[25]   Chronic hepatitis B [J].
Lok, Anna S. F. ;
McMahon, Brian J. .
HEPATOLOGY, 2007, 45 (02) :507-539
[26]   Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B [J].
Marcellin, Patrick ;
Ziol, Marianne ;
Bedossa, Pierre ;
Douvin, Catherine ;
Poupon, Raoul ;
de Ledinghen, Victor ;
Beaugrand, Michel .
LIVER INTERNATIONAL, 2009, 29 (02) :242-247
[27]   EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection [J].
Papatheodoridis, George ;
Buti, Maria ;
Cornberg, Markus ;
Janssen, Harry ;
Mutimer, David ;
Pol, Stanislas ;
Raimondo, Giovanni .
JOURNAL OF HEPATOLOGY, 2012, 57 (01) :167-185
[28]   Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study [J].
Papatheodoridis, George V. ;
Manolakopoulos, Spilios ;
Touloumi, Giota ;
Vourli, Georgia ;
Raptopoulou-Gigi, Maria ;
Vafiadis-Zoumbouli, Irini ;
Vasiliadis, Themistoklis ;
Mimidis, Kostas ;
Gogos, Charalambos ;
Ketikoglou, Ioannis ;
Manesis, Emanuel K. .
GUT, 2011, 60 (08) :1109-1116
[29]   Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review [J].
Papatheodoridis, George V. ;
Lampertico, Pietro ;
Manolakopoulos, Spilios ;
Lok, Anna .
JOURNAL OF HEPATOLOGY, 2010, 53 (02) :348-356
[30]   The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide [J].
Perz, Joseph F. ;
Armstrong, Gregory L. ;
Farrington, Leigh A. ;
Hutin, Yvan J. F. ;
Bell, Beth P. .
JOURNAL OF HEPATOLOGY, 2006, 45 (04) :529-538